Models of excellence: Improving oncology drug development

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 5, 2012, Pages 548-550

  Sharma, M R ^a   Maitland, M L ^a   Ratain, M J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; FLUOROURACIL; FOLINIC ACID; MOTESANIB; PACLITAXEL; PLACEBO;

ADVANCED CANCER; ALZHEIMER DISEASE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG INTERMITTENT THERAPY; DRUG SYNTHESIS; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; METASTASTIC COLORECTAL CANCER; ONCOLOGY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROBABILITY; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER SIMULATION; HUMANS; LUNG NEOPLASMS; MODELS, BIOLOGICAL;

EID: 84867768598     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.99     Document Type: Review

References (10)

1. Box, G.E.P. & Draper, N.R. Empirical Model-Building and Response Surfaces (Wiley, New York, 1987).
2. Lockwood, P. et al. Application of clinical trial simulation to compare proof-of-concept study designs for drugs with slow onset of effect; an example in Alzheimer's disease. Pharm. Res. 23, 2050-2059 (2006).
3. Nixon, R.M. et al. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation. Pharm. Stat. 8, 371-389 (2009).
4. Wang, Y. et al. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin. Pharmacol. Ther. 86, 167-174 (2009).
5. Claret, L. et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J. Clin. Oncol. 27, 4103-4108 (2009).
6. Claret, L. et al. Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer. Clin. Pharmacol. Ther. 92, 631-634 (2012).
7. Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006). (Pubitemid 44917502)
8. Scagliotti, G. et al. An international, randomized, placebo-controlled, doubleblind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) [abstr.]. J. Clin. Oncol. 29 (suppl.) LAB7512 (2011).
9. Mailman, M.D. et al. The NCBI dbGaP database of genotypes and phenotypes. Nat. Genet. 39, 1181-1186 (2007). (Pubitemid 47482671)
10. Berry, D.A. Adaptive clinical trials in oncology. Nat. Rev. Clin. Oncol. 9, 199-207 (2011).